Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.51 |
| ▸ | BACE1 | P56817 | 13/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13538234 | 1.00 | KLK5 (0.51) | KLK5BACE1CYP17A1PSEN1PSEN2 | |
| SCHEMBL13538225 | 1.00 | KLK5 (0.51) | KLK5BACE1CYP17A1PSEN1PSEN2 | |
| SCHEMBL6747621 | 0.89 | KLK5 (0.52) | KLK5BACE1CYP17A1PSEN1PSEN2 | |
| SCHEMBL6747622 | 0.89 | KLK5 (0.52) | KLK5BACE1CYP17A1PSEN1PSEN2 | |
| Hydrochloric Acid SCHEMBL6753321 | 0.88 | KLK5 (0.51) | KLK5BACE1CYP17A1PSEN1PSEN2 | |
| SCHEMBL3984508 | 0.87 | KLK5 (0.65) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL495758 | 0.87 | KLK5 (0.65) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL640670 | 0.87 | KLK5 (0.65) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1481008 | 0.87 | KLK5 (0.65) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL638912 | 0.87 | KLK5 (0.65) | KLK5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | KLK5 1600/4885BACE1 233/4885CYP17A1 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.